Ambergen In the News
PressNovember 2011Agreement between AmberGen and SomaLogic enables use of photocleavable reagent in SOMAmer technologyFebruary 2011AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnosticAnnouncementsSeptember 2011NIH-NCI announces $299K 2-year Phase I SBIR IMAT Award to AmberGen for development of “Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays”March 2011Ambergen receives US patent #7,897,335 on its T2 ELISA technologyOctober 2010AmberGen presents poster at National Cancer Institute’s 11th Principal Investigators IMAT Meeting on proprietary Mass Spectrometry Mutation Detection and High Density Bead-Array technologies. View Abstract (Poster 6 Page 39)October 2010Ambergen receives US patent #7,807,407 on its MASSIVE-PRO technologyOctober 2010Paper published in Breast Cancer Research “An ELISA-based high throughput protein truncation test for inherited breast cancer” on its T2-ELISA technologySeptember 2010NIH-NCI announces $3M SBIR Bridge Award for AmberGen to develop its proprietary prognostic genomic cancer signatures for colorectal cancer recurrenceJune 2010AmberGen Files Patent Application on “Global Proteomic Screening of Random Bead Arrays Using Mass Spectrometry Imaging”June 2010NCI-NIH announces $200K Phase I SBIR Award to AmberGen for development of its “Proteome Bead-Display for Discovery of Tumor Antigens”September 2009Ambergen receives US patent #7,595,198 on novel PC-linker technology for DNA sequencing and protein detectionSeptember 2009Ambergen receives US patent #7,423,122 on its T2 ELISA technologyJune 2009Ambergen receives US patent #7,563,598 on its MASSIVE-PRO technologyJune 2009NIH-NCI announces $1.5M Phase II SBIR Award to AmberGen for development of “Novel Methods for Molecular Analysis of Colorectal Cancer Tissue”June 2009Ambergen receives US patent #7,547,530 on novel PC-linker technology for DNA sequencing and protein detectionMay 2009Ambergen receives US patent #7,534,861 on its T2 ELISA technologyApril 2009Ambergen receives US patent #7,524,941 on its TRAMPE technologyFebruary 2009Ambergen receives US patent #7,485,427 on novel PC-linker technology for DNA sequencing and protein detectionJuly 2008Paper published in Analytical Biochemistry on Ambergen's novel technology "Photocleavage Based Affinity Purification and Printing of Cell-Free Expressed Proteins: Application to Proteome Microarrays"July 2008NIH-NCI announces $1.2 million Phase II SBIR Award for Ambergen to develop and commercialize a high sensitivity drug resistance assay for CML patientsJune 2008Ambergen signs agreement with Ananomouse, Inc. to develop cancer recurrence assaysMarch 2008Ambergen receives US patent #7,339,045 on novel PC-linker technology for DNA sequencing and protein detectionDecember 2007Ambergen receives two US patents (#7,312,060 and #7,312,038) on its protein detection and isolation technology with broad applications including DNA sequencingNovember 2007Dr. Mark Lim, Director of Proteomics, co-chairs the Advances in Proteomics: New Technologies I Session at the 2007 Annual Meeting of the American Electrophoresis Society in Salt Lake City, UT and also delivers talk on cell-free expressed proteomicsNovember 2007Ambergen opens new corporate headquarters and laboratories in Watertown, MAOctober 2007Ambergen receives US patent #7,288,372 on new methods to create designer proteins by TRAMPE for biomedical applicationsSeptember 2007NCI-NIH announces $1.3 million Phase I SBIR Award for Ambergen to develop prognostic CRC assays based on molecular profiling of tumorsAugust 2007Ambergen receives US patent #7,252,932 on methods to detect protein truncations using gel-free methodsAugust 2007Dr. Christopher Sears joins Ambergen, Inc. as Chief Scientific OfficerMay 2007Ambergen receives US patent #7,211,394 and #7,195,874 on methods of using its proprietary photocleavable linkersApril 2007NIAID-NIH announces $2.5 million Phase II SBIR Award to Ambergen to develop and commercialize high sensitivity HIV drug resistance assaysMarch 2007NIAID-NIH announces $2.0 million Phase II SBIR Award for Ambergen to develop and commercialize diagnostic assays for autoimmune diseaseFebruary 2007Dr. James Han joins Ambergen as Director of New Assay DevelopmentJanuary 2007Ambergen receives US patent #7,169,558 for its TRAMPE technology |
©2012 Ambergen Inc. All Rights Reserved. Terms & Conditions